Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
ATP-binding cassette (ABC) transporters, P-glycoprotein (P-gp, ABCB1) and ABCG2, are membrane proteins that couple the energy derived from ATP hydrolysis to efflux many chemically diverse compounds across the plasma membrane, thereby playing a critical and important physiological role in protecting cells from xenobiotics. These transporters are also implicated in the development of multidrug resistance (MDR) in cancer cells that have been treated with chemotherapeutics. One approach to blocking the efflux capability of an ABC transporter in a cell or tissue is inhibiting the activity of the transporters with a modulator. Since ABC transporter modulators can be used in combination with chemotherapeutics to increase the effective intracellular concentration of anticancer drugs, the possible impact of modulators of ABC drug transporters is of great clinical interest. Another possible clinical use of modulators that has recently attracted attention is their ability to increase oral bioavailability or increase tissue penetration of drugs transported by the transporters. Several preclinical and clinical studies have been performed to evaluate the feasibility and the safety of this approach. The primary focus of this review is to discuss progress made in recent years in the identification and applicability of compounds that may serve as ABC transporter modulators and the possible role of these compounds in altering the pharmacokinetics and pharmacodynamics of therapeutic drugs used in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 1×
“MRP1 (ABCC1) was the first member of the MRP family to be identified (in 1992) and has been linked to the development of MDR (22).”
BackgroundA "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“MRP1 transports some substrates conjugated with glucuronide, sulfate or glutathione, vinca alkaloids, anthracyclines, methotrexate and also leukotriene C4, which is an endogenous substrate for the transporter (24, 25).”
BackgroundThe molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein research
Gottesman, M. M., & Ling, V. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.060 · Cited by 558 · cited 2×
“As stated above, inhibition of ABC drug transporters by modulators may be used to achieve two independent clinical objectives: (1) reversal of MDR in drug resistant tumors during chemotherapy (2) increasing a drug’s exposure in body {tissues} for purposes such as increasing oral bioavailability or enhanced brain accum…”
BackgroundMethod
Cited by
The Blood-Testis Barrier and Its Implications for Male Contraception
Cheng, C. Y., & Mruk, D. D. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.002790 · Cited by 927
Délye, C. (2013) · Pest Management Science · doi:10.1002/ps.3318 · Cited by 475
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
“Inhibition of P-gp and MRP simultaneously could be beneficial for brain targeted delivery [68].”
BackgroundEpigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death
Cheng, G., Zielonka, J., Dranka, B. P., McAllister, D., Mackinnon, A. C., Joseph, J., & Kalyanaraman, B. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3928 · Cited by 263
Ward, A. B., Szewczyk, P., Grimard, V., Lee, C.-W., Martinez, L., Doshi, R., Caya, A., Villaluz, M., Pardon, E., Cregger, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309275110 · Cited by 256
Everted gut sac model as a tool in pharmaceutical research: limitations and applications
Alam, M. A., Al-Jenoobi, F. I., & Al-mohizea, A. M. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01391.x · Cited by 221
“The role of P-gp in the development of multidrug-resistance in cancer chemotherapy has been established and several modulators have been identified.([14]) The influx transporters are members of the solute carrier transporter (SLC) family; a number of SLC transporters have been identified.”
BackgroundThe ABCs of Candida albicans multidrug transporter Cdr1
Prasad, R., Banerjee, A., Khandelwal, N. K., & Dhamgaye, S. (2015) · Eukaryotic Cell · doi:10.1128/ec.00137-15 · Cited by 123
Oral lipid nanomedicines: Current status and future perspectives in cancer treatment
El Moukhtari, S. H., Rodríguez-Nogales, C., & Blanco-Prieto, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.004 · Cited by 70
Li, J., Wu, J., Bao, X., Honea, N., Xie, Y., Kim, S., Sparreboom, A., & Sanai, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0983 · Cited by 68
“, imatinib, methotrexate, paclitaxel, fentanyl, and pentazocine) are also the substrates of ABCB1 and/or ABCG2 (25-29).”
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
Lima, T. S., Souza, L. O., Iglesias-Gato, D., Elversang, J., Jørgensen, F. S., Kallunki, T., Røder, M. A., Brasso, K., & Moreira, J. M. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869461 · Cited by 26
“We have previously implemented a strategy in drug development based on biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy (Stenvang et al., 2013).”
Method
Metadata
- Authors
- Shukla, S., Ohnuma, S., & V. Ambudkar, S.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-05-01
- Volume
- 12
- Issue
- 5
- Pages
- 621-630
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2118937378
- Cited by
- 233
- References
- 5
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.